Programs & Tools:
IIS: HL7 Standard Code Set CVX - Vaccines Administered
Updated: September 23, 2008
Immunization Information Systems Home (IIS) pages:
Get Email Updates
Printable version of CVX -- Vaccines Administered
The CDC's National Center of Immunization and Respiratory Diseases (NCIRD) maintains the HL7 external code set CVX. The implementation of the HL7 standard for immunization data exchange is described in Chapter 4 of the HL7 standard. The codes in HL7 Version 2.3 table 0292, represented the initial content of the external CVX code set. Since vaccines have to be added to this table more quickly than new versions of HL7 are released, this document represents the most up-to-date version of the CVX code set. Items have been added. Others have been added for planning purposes, pending FDA approval.
Code | Short Description | Full Vaccine Name |
---|---|---|
54 | adenovirus, type 4 | adenovirus vaccine, type 4, live, oral |
55 | adenovirus, type 7 | adenovirus vaccine, type 7, live, oral |
82 | adenovirus, NOS1 | adenovirus vaccine, NOS |
24 | anthrax | anthrax vaccine |
19 | BCG | Bacillus Calmette-Guerin vaccine |
27 | botulinum antitoxin | botulinum antitoxin |
26 | cholera | cholera vaccine |
29 | CMVIG | cytomegalovirus immune globulin, intravenous |
56 | dengue fever | dengue fever vaccine |
12 | diphtheria antitoxin | diphtheria antitoxin |
28 | DT (pediatric) | diphtheria and tetanus toxoids, adsorbed for pediatric use |
20 | DTaP | diphtheria, tetanus toxoids and acellular pertussis vaccine |
106 | DTaP, 5 pertussis antigens6 | diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens |
107 | DTaP, NOS | diphtheria, tetanus toxoids and acellular pertussis vaccine, NOS |
110 | DTaP-Hep B-IPV | DTaP-hepatitis B and poliovirus vaccine |
50 | DTaP-Hib | DTaP-Haemophilus influenzae type b conjugate vaccine |
120 | DTaP-Hib-IPV | diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) Changes last made on Feb. 28, 2006 |
130 | DTaP-IPV | Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated (Changes made July 25, 2008) |
01 | DTP | diphtheria, tetanus toxoids and pertussis vaccine |
22 | DTP-Hib | DTP-Haemophilus influenzae type b conjugate vaccine |
102 | DTP-Hib-Hep B | DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine |
57 | hantavirus | hantavirus vaccine |
52 | Hep A, adult | hepatitis A vaccine, adult dosage |
83 | Hep A, ped/adol, 2 dose | hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule |
84 | Hep A, ped/adol, 3 dose | hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule |
31 | Hep A, pediatric, NOS | hepatitis A vaccine, pediatric dosage, NOS |
85 | Hep A, NOS | hepatitis A vaccine, NOS |
104 | Hep A-Hep B | hepatitis A and hepatitis B vaccine |
30 | HBIG | hepatitis B immune globulin |
08 | Hep B, adolescent or pediatric | hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
42 | Hep B, adolescent/high risk infant2 | hepatitis B vaccine, adolescent/high risk infant dosage |
43 | Hep B, adult4 | hepatitis B vaccine, adult dosage |
44 | Hep B, dialysis | hepatitis B vaccine, dialysis patient dosage |
45 | Hep B, NOS | hepatitis B vaccine, NOS |
58 | Hep C | hepatitis C vaccine |
59 | Hep E | hepatitis E vaccine |
60 | herpes simplex 2 | herpes simplex virus, type 2 vaccine |
46 | Hib (PRP-D) | Haemophilus influenzae type b vaccine, PRP-D conjugate |
47 | Hib (HbOC) | Haemophilus influenzae type b vaccine, HbOC conjugate |
48 | Hib (PRP-T) | Haemophilus influenzae type b vaccine, PRP-T conjugate |
49 | Hib (PRP-OMP) | Haemophilus influenzae type b vaccine, PRP-OMP conjugate |
17 | Hib, NOS | Haemophilus influenzae type b vaccine, conjugate NOS |
51 | Hib-Hep B | Haemophilus influenzae type b conjugate and Hepatitis B vaccine |
61 | HIV | human immunodeficiency virus vaccine |
118 | HPV, bivalent | human papilloma virus vaccine, bivalent Changes last made on Feb. 28, 2006 |
62 | HPV, quadrivalent | human papilloma virus vaccine, quadrivalent Changes last made on Feb. 28, 2006 |
86 | IG | immune globulin, intramuscular |
87 | IGIV | immune globulin, intravenous |
14 | IG, NOS | immune globulin, NOS |
111 | influenza, live, intranasal | influenza virus vaccine, live, attenuated, for intranasal use |
15 | influenza, split (incl. purified surface antigen) | influenza virus vaccine, split virus (incl. purified surface antigen) |
16 | influenza, whole | influenza virus vaccine, whole virus |
88 | influenza, NOS | influenza virus vaccine, NOS |
123 | influenza, H5N1-1203 |
influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile) (Changes made September 23, 2008) |
10 | IPV | poliovirus vaccine, inactivated |
02 | OPV | poliovirus vaccine, live, oral |
89 | polio, NOS | poliovirus vaccine, NOS |
39 | Japanese encephalitis | Japanese encephalitis vaccine |
63 | Junin virus | Junin virus vaccine |
64 | leishmaniasis | leishmaniasis vaccine |
65 | leprosy | leprosy vaccine |
66 | Lyme disease | Lyme disease vaccine |
03 | MMR | measles, mumps and rubella virus vaccine |
04 | M/R | measles and rubella virus vaccine |
94 | MMRV | measles, mumps, rubella, and varicella virus vaccine |
67 | malaria | malaria vaccine |
05 | measles | measles virus vaccine |
68 | melanoma | melanoma vaccine |
32 | meningococcal | meningococcal polysaccharide vaccine (MPSV4) |
103 | meningococcal C conjugate | meningococcal C conjugate vaccine |
114 | meningococcal A,C,Y,W-135 diphtheria conjugate | meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4) |
108 | meningococcal, NOS | meningococcal vaccine, NOS Changes last made on May 10, 2006 |
07 | mumps | mumps virus vaccine |
69 | parainfluenza-3 | parainfluenza-3 virus vaccine |
11 | pertussis | pertussis vaccine |
23 | plague | plague vaccine |
33 | pneumococcal | pneumococcal polysaccharide vaccine |
100 | pneumococcal conjugate | pneumococcal conjugate vaccine, polyvalent |
109 | pneumococcal, NOS | pneumococcal vaccine, NOS |
70 | Q fever | Q fever vaccine |
18 | rabies, intramuscular injection | rabies vaccine, for intramuscular injection |
40 | rabies, intradermal injection | rabies vaccine, for intradermal injection |
90 | rabies, NOS | rabies vaccine, NOS |
72 | rheumatic fever | rheumatic fever vaccine |
73 | Rift Valley fever | Rift Valley fever vaccine |
34 | RIG | rabies immune globulin |
119 | rotavirus, monovalent | rotavirus, live, monovalent vaccine Changes last made on Feb. 28, 2006 |
122 | rotavirus, NOS1 | rotavirus vaccine, NOS Changes last made on June 1, 2006 |
116 | rotavirus, pentavalent | rotavirus, live, pentavalent vaccine Changes last made on Feb. 28, 2006 |
74 | rotavirus, tetravalent | rotavirus, live, tetravalent vaccine Changes last made on Feb. 28, 2006 |
71 | RSV-IGIV | respiratory syncytial virus immune globulin, intravenous |
93 | RSV-MAb | respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular |
06 | rubella | rubella virus vaccine |
38 | rubella/mumps | rubella and mumps virus vaccine |
76 | Staphylococcus bacterio lysate | Staphylococcus bacteriophage lysate |
113 | Td (adult) | tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use |
09 | Td (adult) | tetanus and diphtheria toxoids, adsorbed for adult use |
115 | Tdap | tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed Changes last made on May 10, 2006 |
35 | tetanus toxoid | tetanus toxoid, adsorbed |
112 | tetanus toxoid, NOS | tetanus toxoid, NOS |
77 | tick-borne encephalitis | tick-borne encephalitis vaccine |
13 | TIG | tetanus immune globulin |
95 | TST-OT tine test | tuberculin skin test; old tuberculin, multipuncture device |
96 | TST-PPD intradermal | tuberculin skin test; purified protein derivative solution, intradermal |
97 | TST-PPD tine test | tuberculin skin test; purified protein derivative, multipuncture device |
98 | TST, NOS | tuberculin skin test; NOS |
78 | tularemia vaccine | tularemia vaccine |
91 | typhoid, NOS | typhoid vaccine, NOS |
25 | typhoid, oral | typhoid vaccine, live, oral |
41 | typhoid, parenteral | typhoid vaccine, parenteral, other than acetone-killed, dried |
53 | typhoid, parenteral, AKD (U.S. military) | typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) |
101 | typhoid, ViCPs | typhoid Vi capsular polysaccharide vaccine |
75 | vaccinia (smallpox) | vaccinia (smallpox) vaccine |
105 | vaccinia (smallpox) diluted | vaccinia (smallpox) vaccine, diluted |
79 | vaccinia immune globulin | vaccinia immune globulin |
21 | varicella | varicella virus vaccine |
81 | VEE, inactivated | Venezuelan equine encephalitis, inactivated |
80 | VEE, live | Venezuelan equine encephalitis, live, attenuated |
92 | VEE, NOS | Venezuelan equine encephalitis vaccine, NOS |
36 | VZIG | varicella zoster immune globulin |
117 | VZIG (IND) | varicella zoster immune globulin (Investigational New Drug) Changes last made on Feb. 28, 2006 |
37 | yellow fever | yellow fever vaccine |
121 | zoster | zoster vaccine, live Changes last made on June 1, 2006 |
998 | no vaccine administered5 | no vaccine administered |
999 | unknown | unknown vaccine or immune globulin |
99 | RESERVED - do not use3 | RESERVED - do not use |
Usage Notes:
1NOS=not otherwise specified; avoid using NOS codes except to record historical records that lack the indicated specificity.
2As of August 27, 1998, Merck ceased distribution of their adolescent/high risk infant hepatitis B vaccine dosage. Code 42 should only be used to record historical records. For current administration of hepatitis B vaccine, pediatric/adolescent dosage, use code 08.
3Code 99 will not be used in this table to avoid confusion with code 999.
4As of September 1999, a 2-dose hepatitis B schedule for adolescents (11-15 year olds) was FDA approved for Merck's Recombivax HB® adult formulation. Use code 43 for both the 2-dose and the 3- dose schedules.
5Code 998 was added for use in VXR and VXU HL7 messages where the OBX segment is nested with the RXA segment, but the message does not contain information about a vaccine administration. An example of this use is to report the vaccines due next for a patient when no vaccine administration is being reported.
6As of May 2002, the FDA approved Aventis Pasteur's DTaP Daptacel for use in the U.S. Aventis Pasteur also manufactures the DTaP vaccine Tripedia. Daptacel contains 5 pertussis antigens, while Tripedia contains 2 pertussis antigens. To distinguish between the two Aventis Pasteur DTaP vaccines, code 106 was added to represent Daptacel. Use code 106 for Daptacel and code 20 for Tripedia and other DTaP vaccines.
For further information on HL7 immunization data exchange and the CVX code set, contact the IIS Technical Assistance Team at:
Immunization Information System Support Branch - Informatics
1600 Clifton Road
Mailstop: E-62
Atlanta, GA 30333
.pdf files: To view and print the .pdf files on this site, you will need Adobe Acrobat Reader. Use this link to obtain a free copy of Adobe Acrobat Reader (exit). We highly recommend that you upgrade to the latest version if haven't already.
Content last reviewed on July 25, 2008
Content Source: National Center for Immunization and Respiratory Diseases